NO306902B1 - Anvendelse av indolokarbazolderivater til fremstilling av et medikament for å behandle en patologisk tilstand av prostata - Google Patents

Anvendelse av indolokarbazolderivater til fremstilling av et medikament for å behandle en patologisk tilstand av prostata

Info

Publication number
NO306902B1
NO306902B1 NO954816A NO954816A NO306902B1 NO 306902 B1 NO306902 B1 NO 306902B1 NO 954816 A NO954816 A NO 954816A NO 954816 A NO954816 A NO 954816A NO 306902 B1 NO306902 B1 NO 306902B1
Authority
NO
Norway
Prior art keywords
halogen
prostate
medicament
treating
manufacture
Prior art date
Application number
NO954816A
Other languages
English (en)
Norwegian (no)
Other versions
NO954816L (no
NO954816D0 (no
Inventor
Craig A Dionne
Patricia C Contreras
Chikara Murakata
Original Assignee
Cephalon Inc
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc, Kyowa Hakko Kogyo Kk filed Critical Cephalon Inc
Publication of NO954816D0 publication Critical patent/NO954816D0/no
Publication of NO954816L publication Critical patent/NO954816L/no
Publication of NO306902B1 publication Critical patent/NO306902B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO954816A 1993-05-28 1995-11-27 Anvendelse av indolokarbazolderivater til fremstilling av et medikament for å behandle en patologisk tilstand av prostata NO306902B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6917893A 1993-05-28 1993-05-28
US9662293A 1993-07-22 1993-07-22
PCT/US1994/006082 WO1994027982A1 (en) 1993-05-28 1994-05-27 Use of indolocarbazole derivatives to treat a pathological condition of the prostate

Publications (3)

Publication Number Publication Date
NO954816D0 NO954816D0 (no) 1995-11-27
NO954816L NO954816L (no) 1996-01-26
NO306902B1 true NO306902B1 (no) 2000-01-10

Family

ID=26749764

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954816A NO306902B1 (no) 1993-05-28 1995-11-27 Anvendelse av indolokarbazolderivater til fremstilling av et medikament for å behandle en patologisk tilstand av prostata

Country Status (14)

Country Link
US (2) US5516771A (de)
EP (2) EP0699204B1 (de)
JP (2) JP3344586B2 (de)
KR (1) KR100201343B1 (de)
AT (1) ATE165097T1 (de)
AU (1) AU679752B2 (de)
CA (1) CA2163904C (de)
DE (1) DE69409641T2 (de)
DK (1) DK0699204T3 (de)
ES (1) ES2118414T3 (de)
FI (2) FI113537B (de)
NO (1) NO306902B1 (de)
NZ (1) NZ267337A (de)
WO (1) WO1994027982A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
ES2123873T3 (es) * 1994-08-04 1999-01-16 Hoffmann La Roche Pirrolocarbazol.
US5650407A (en) * 1995-04-05 1997-07-22 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
US5686444A (en) 1995-04-05 1997-11-11 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
US6197293B1 (en) 1997-03-03 2001-03-06 Calydon, Inc. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
BR9710706A (pt) * 1996-05-01 1999-08-17 Lilly Co Eli Tratamento terap-utico para doen-as relacionadas a vegf
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
US6875865B1 (en) 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
BR9710693A (pt) 1996-06-25 2000-01-11 Cephalon Inc Uso de um derivado de k-252a para o tratamento do nervo central ou periférico e super produção de citoquinona.
EA002525B1 (ru) * 1997-08-15 2002-06-27 Сефалон Инк. Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы
DK1044203T3 (da) 1997-12-31 2003-07-14 Cephalon Inc 3'-epimere K-252a-derivater
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
CN1329034C (zh) 1998-09-25 2007-08-01 赛福伦公司 预防/治疗感觉毛细胞和耳蜗神经元损伤的药物
ATE406907T1 (de) * 1998-10-28 2008-09-15 Cornell Res Foundation Inc Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
WO2001010440A1 (en) * 1999-08-09 2001-02-15 Trustees Of Dartmouth College COMPOSITIONS AND METHODS TO ENHANCE CANCER CHEMOTHERAPY IN p53 DEFECTIVE TUMORS
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
AR035971A1 (es) * 2001-05-16 2004-07-28 Cephalon Inc Metodos para el tratamiento y la prevencion del dolor
IL144583A0 (en) * 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
CN101283275A (zh) 2005-10-11 2008-10-08 默克专利有限公司 趋化因子表达的依赖egfr的调控和对肿瘤的诊断和治疗的影响及其副作用
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
AU2013362134B2 (en) 2012-12-21 2018-07-05 Sykehuset Sorlandet Hf EGFR targeted therapy of neurological disorders and pain

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62155285A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62155284A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62240689A (ja) * 1986-04-07 1987-10-21 Meiji Seika Kaisha Ltd Ｓｆ−２３７０物質誘導体及びその製法
JPH0826037B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
JPH0826036B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
US5073633A (en) * 1989-03-23 1991-12-17 Bristol-Myers Company BMY-41950 antitumor antibiotic
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
CA2112799A1 (en) * 1991-07-03 1993-01-21 Stephen P. Squinto Method and assay system for neurotrophin activity
WO1993008809A1 (en) * 1991-11-08 1993-05-13 The University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
US6271242B1 (en) * 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders

Also Published As

Publication number Publication date
CA2163904C (en) 2000-01-25
JP3344586B2 (ja) 2002-11-11
NO954816L (no) 1996-01-26
WO1994027982A1 (en) 1994-12-08
FI114864B (fi) 2005-01-14
NO954816D0 (no) 1995-11-27
EP0699204A4 (de) 1996-01-10
DK0699204T3 (da) 1999-02-22
AU6960794A (en) 1994-12-20
EP0839814A2 (de) 1998-05-06
EP0699204B1 (de) 1998-04-15
JP2002504064A (ja) 2002-02-05
KR100201343B1 (ko) 1999-06-15
DE69409641T2 (de) 1998-11-26
EP0839814A3 (de) 1998-09-16
US5654427A (en) 1997-08-05
FI955709L (fi) 1996-01-03
DE69409641D1 (de) 1998-05-20
JP2002356487A (ja) 2002-12-13
FI20031516A7 (fi) 2003-10-16
FI113537B (fi) 2004-05-14
EP0699204A1 (de) 1996-03-06
JP3727613B2 (ja) 2005-12-14
KR960702838A (ko) 1996-05-23
AU679752B2 (en) 1997-07-10
NZ267337A (en) 2005-01-28
CA2163904A1 (en) 1994-12-08
US5516771A (en) 1996-05-14
ATE165097T1 (de) 1998-05-15
ES2118414T3 (es) 1998-09-16
FI955709A0 (fi) 1995-11-27

Similar Documents

Publication Publication Date Title
NO954816D0 (no) Anvendelse av indolokarbazolderivater for å behandle en patologisk tilstand av prostata
FI911443A0 (fi) Foerfarande foer framstaellning av 3,5-di-tert.butyl-4-hydroxifenylmetylenderivat av 2-substituerade tiazolidinoner, oxazolidinoner och imidazolidinoner med antiinflammatorisk aktivitet.
ATE152111T1 (de) K-252a derivate
TW222638B (de)
DE69104593D1 (de) Herstellung und Verwendung von N-Jodopropargyl-oxycarbonylaminosäure-Estern als antimicrobielle Mittel.
ATE184483T1 (de) Spirooxathiolan-quinuclidin-derivat zur behandlung des sjögren-syndroms
ATE143014T1 (de) Benzimidazol-derivate und therapeutische, diese enthaltende mittel gegen ulcer
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
AU2028097A (en) Amino- and hydroxysubstituted triphenyl-s-triazines as stabilizers
DE69502223D1 (de) Neue Verwendung von 1Alpha-fluor-25-hydroxy-16-en-23-yn-cholecalciferol
FI914007A0 (fi) 4-substituerade dihydropyrido (4,3-d) pyrimidiner som smaertslindrande och lokala inflammationshaemmande medel vid vaord av hudsjukdomar.
DE3867652D1 (de) N-substituierte 3,4-dihydropyrimidinverbindungen als mittel zur behandlung von erkrankungen des kardiovaskularen systems.
DK325188D0 (da) Hidtil ukendte benzazepinderivater
JPS56104834A (en) Anthracenone compound
DE69823650D1 (de) Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
TR200102205T2 (tr) Anti-konvülsan türevlerinin bulimia nevruza tedavisinde kullanılmaları.
FI852249A0 (fi) Foerfarande foer framstaellning av nya isoxazolokinolinoner.
TW262462B (de)
ATE28876T1 (de) Triorganozinnacetylsalicylate und diese enthaltende biozide mittel.
MX9702211A (es) Hidroxifenil triazinas.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees